Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrenkel Topping Regulatory News (FEN)

Share Price Information for Frenkel Topping (FEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 52.00
Bid: 50.00
Ask: 54.00
Change: 0.00 (0.00%)
Spread: 4.00 (8.00%)
Open: 52.00
High: 52.00
Low: 52.00
Prev. Close: 52.00
FEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

22 Aug 2023 07:00

RNS Number : 9809J
Frenkel Topping Group PLC
22 August 2023
 

The information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended. With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Frenkel Topping Group plc

("Frenkel Topping", the "Company" or the "Group") 

Pre-Close Trading Update to 30th June 2023

Ahead of the announcement of its half-year results due on 29 September 2023, Frenkel Topping (AIM: FEN), a specialist financial and professional services firm operating within the personal injury and clinical negligence marketplace, is pleased to provide the following trading update for the six month period ended 30th June 2023 ("HY2023") and an outlook for the current financial year ("FY2023").

H1 2023*

(£m)

H1 2022*

(£m)

% change

FY2022

Full year (£m)

Revenue

16.0

11.1

44%

24.8

Recurring revenue

5.9

5.4

9%

11.0

Gross profit

6.6

5.0

32%

11.1

EBITDA**

3.5

2.7

30%

6.1

Profit attributable to shareholders

1.7

0.9

89%

1.7

EPS (basic)

1.4 pence

0.8 pence

75%

1.5 pence

Cash generated from operating activities

1.5

0.6

150%

0.7

 

*Unaudited

**EBITDA before share based compensation, acquisition strategy, integration and reorganisation costs

Assets Under Management ("AUM") has grown to £1,261m (HY2022: £1,155m). The Company is also pleased to again report its outstanding client retention rate maintained at 99%.

This performance demonstrates the Company's continued resilience in a challenging financial market, as well as the progress made by the Company in diversifying revenue streams via its focused acquisition strategy and consolidation of the Personal Injury (PI) and Clinical Negligence (CN) space.

Of note is the performance of the Group's discretionary fund manager, Ascencia Investment Management ("Ascencia"), where assets on a DFM Mandate increased to £761m (HY2022: £667m).

As we saw in the previous financial year the Group's recurring revenue has continued to be supplemented by transactional revenue delivered by the Group's businesses acquired during the last 3 years, underlining the success of diversifying revenue streams, seeing total revenues at £16m, but with a consequential change in margin profile.

The Company's group businesses have enjoyed real momentum in the period with Cardinal Management Limited ("Cardinal") adding two new sites to its Major Trauma Centre portfolio in recent months through John Radcliffe Hospital, run by Oxford University Hospitals NHS Foundation Trust and Alder Hey Children's Hospital opting to join Cardinal after a competitive tender process.

Outlook

The business goes into the second half of the year carrying real momentum from H1, benefiting from the diversification of revenue and encouraging growth in transactional revenue. We do expect financial markets to remain challenging, which will continue to moderately impact AUM growth and the Company's recurring revenue generated from this. However, the Board maintains confidence in the full year outturn and its expectation for the year which are tracking in line with management's expectation.

Notice of results and update on strategy

Final, unaudited results for the six months ended 30th June 2023 are expected to be announced on 29 September 2023. 

* The financial expectations noted above are preliminary. Adj. EBITDA defined as before share based compensation, acquisition, integration and reorganisation costs.

 

For further information:     

Frenkel Topping Group plc

www.frenkeltoppinggroup.co.uk

Richard Fraser, Chief Executive Officer

Tel: 0161 886 8000

finnCap Ltd (Nominated Advisor & Broker)

Tel: 020 7220 0500

Carl Holmes/Abigail Kelly/Milesh Hindocha (Corporate Finance)

Tim Redfern / Charlotte Sutcliffe (ECM)

About Frenkel Topping Group

The Frenkel Topping Group of companies specialises in providing financial advice and asset protection services to clients at times of financial vulnerability, with particular expertise in the field of personal injury (PI) and clinical negligence (CN).

For more than 30 years the Group has worked with legal professionals and injured clients themselves to provide pre-settlement, at-settlement and post-settlement services to help achieve the best long-term outcomes for clients after injury. It boasts a client retention rate of 99%.

Frenkel Topping Group is focused on consolidating the fragmented PI and CN space in order to provide the most comprehensive suite of services to clients and deliver a best-in-class service offering from immediately after injury or illness and for the rest of their lives.

The group's services include the Major Trauma Signposting Partnership service inside NHS Major Trauma Centres, expert witness, costs, tax and forensic accountancy, independent financial advice, investment management, and care and case management.

The Group's discretionary fund manager, Ascencia, manages financial portfolios for clients in unique circumstances, often who have received a financial settlement after litigation. In recent years Ascencia has diversified its portfolios to include a Sharia-law-compliant portfolio and a number of ESG portfolios in response to increased interest in socially responsible investing (SRI).

Frenkel Topping has earned a reputation for commercial astuteness underpinned by a strong moral obligation to its clients, employees and wider society, with a continued focus on its Environmental, Social and Governance (ESG) impact.

For more information visit: www.frenkeltoppinggroup.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSELFMFEDSEFA
Date   Source Headline
12th Jan 20127:00 amRNSTrading Statement
30th Nov 20114:12 pmRNSDirector/PDMR Shareholding
23rd Nov 201111:34 amRNSDirector/PDMR Shareholding
22nd Nov 20113:01 pmRNSEmployee Benefit Trust share purchase
27th Oct 20116:11 pmRNSDirector Shareholding and Holding in Company
20th Sep 20113:41 pmRNSDirector/PDMR Shareholding
6th Sep 201112:41 pmRNSExercise of options
21st Jul 20117:00 amRNSHalf Yearly Report
1st Jul 20117:00 amRNSChange of Adviser
20th Jun 20112:20 pmRNSDirector/PDMR Shareholding
15th Jun 20115:12 pmRNSCapital Reorganisation
13th Jun 20114:00 pmRNSHolding(s) in Company
10th Jun 201112:57 pmRNSCapital Reorganisation Update
8th Jun 20118:18 amRNSHolding(s) in Company
10th May 201110:31 amRNSResult of AGM
10th May 20117:00 amRNSAGM Statement
4th Apr 201112:09 pmRNSHolding(s) in Company
29th Mar 201112:33 pmRNSNotice of AGM
28th Mar 20111:58 pmRNSDirector/PDMR Shareholding
28th Mar 201110:34 amRNSDirector/PDMR Shareholding
24th Mar 20111:52 pmRNSIssue of Options
24th Mar 20117:00 amRNSFinal Results
2nd Feb 20114:21 pmRNSHolding(s) in Company
1st Feb 20119:48 amRNSHolding(s) in Company
15th Dec 20104:07 pmRNSDirectorate Change
30th Sep 20109:42 amRNSTotal Voting Rights
28th Sep 20104:27 pmRNSDirector/PDMR Shareholding
21st Sep 20102:38 pmRNSDirector/PDMR Shareholding
13th Sep 20104:41 pmRNSDirector/PDMR Shareholding
1st Sep 20102:59 pmRNSDirector/PDMR Shareholding
1st Sep 20102:55 pmRNSExercise of Options
11th Aug 20102:27 pmRNSDirector/PDMR Shareholding
9th Aug 20109:51 amRNSHalf Yearly Report
15th Jun 201010:24 amRNSDirector/PDMR Shareholding
8th Jun 201010:20 amRNSDirector/PDMR Shareholding
26th Apr 20109:46 amRNSDirector/PDMR Shareholding
13th Apr 201010:10 amRNSDirector/PDMR Shareholding
31st Mar 20109:10 amRNSFinal Results
26th Nov 20092:41 pmRNSDirector/PDMR Shareholding
24th Nov 20099:12 amRNSDirector/PDMR Shareholding
12th Nov 20099:19 amRNSDirector/PDMR Shareholding
30th Sep 20097:00 amRNSTotal Voting Rights
11th Sep 20097:51 amRNSDirector/PDMR Shareholding - Replacement
10th Sep 20098:48 amRNSDirector/PDMR Shareholding
4th Sep 200912:21 pmRNSIssue of Equity
16th Jul 20099:17 amRNSHalf Yearly Report
25th Mar 200911:06 amRNSDirector/PDMR Shareholding
24th Mar 20099:58 amRNSPreliminary Results
3rd Nov 20083:11 pmRNSDirector/PDMR Shareholding
30th Sep 20082:16 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.